This report today may be helping
Sydney - Wednesday - April 26: (RWE Aust Business News) - These were some of the developments in the biotech sector over the past week - from ABN AMRO Morgans: News & Research *************** Ventracor (VCR) Buy; Price Target: $1.70; Share Price: 86c; Market Cap: $224m. The Center for Medicare and Medicaid Services (CMS) in the US has proposed changes in reimbursement rates for hospital inpatient procedures. The changes target reimbursement loopholes used by specialty hospitals and seek to trim the amount spent by the CMS on devices such as pacemakers, defibrillators and stents. CMS officials say the proposed rule will mean that payments for hospital stays will "more accurately" reflect the costs of providing services. Some of the major heart device companies in the US such as J&J, St Jude and Boston Scientific's share prices fell in response to this news. Ventracor's left ventricular assist device is not expected to be effected by these proposed changes in any material way. We remain comfortable with our price target.
VCR
ventracor limited
